Is CERS above its 150-day moving average?

CERS is currently above its 150-day moving average by 39.49%. The MA150 sits at $1.95.

What is CERS's RSI right now?

CERS's 14-period RSI is 78.4. This is in overbought territory (above 70).

Is CERS's MACD bullish or bearish?

CERS's MACD histogram reads +0.0793. A positive histogram means short-term momentum is leaning bullish.

How are CERS's technical signals calculated?

Scanance computes CERS's technicals daily after market close from end-of-day OHLCV data. MA150 and MA200 are simple moving averages. RSI uses Wilder's 14-period smoothing. MACD uses 12/26/9 exponential moving averages. Volume ratio compares current volume to the 20-day average.

Scanance does not provide investment advice. The technical readouts on this page are pattern matches against deterministic indicator rules — they are not buy or sell recommendations. Always do your own research and consider consulting a licensed financial professional before making any trade.

CE

Cerus Corporation

CERSHealthcareNASDAQ

Medical Devices · Last scanned May 28, 2026

PriceMA150MA200

Loading chart…

End-of-day data · ScananceOpen live chart on TradingView ↗

Indicator snapshot

MA150+39.49%

$1.95

Price above medium-term moving average.

MA200+51.96%

$1.79

Above long-term trend line.

RSI-14overbought

78.4

Above 70 — may be overbought.

MACDpositive

+0.0793

Histogram positive — upward momentum.

Financials · Annual

Revenue

$206.1M

+14.3% YoY

Net Income

-$15.6M

+25.3% YoY

EBITDA

-$5.5M

+45.0% YoY

Scan Results

Daily timeframe

1 of 4 indicators bearish as of May 4

DateIndicatorDetails

About Cerus Corporation

Cerus Corporation operates as a biomedical products company. With a market capitalization of $545.0M, it sits in small-cap territory. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.

Key stats

Market Cap$545.0M

Fwd P/E-90.67

EPS$-0.05

Beta1.63

52W Change+117.6%

ROE-15.4%

Analysis

Cerus Corporation carries $97.4M in total debt against $80.4M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Return on equity stands at -15.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $130.9M (2021) to $206.1M (2025), reflecting a 58% increase over the period.

With a beta above 1.5, CERS tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Cerus Corporation and its sector.

Links

Company website ↗

Cerus Corporation

News & analytics is part of Premium.

Technical readouts are part of Premium.